nodes	percent_of_prediction	percent_of_DWPC	metapath
Raloxifene—AOX1—Methotrexate—muscle cancer	0.428	0.6	CbGbCtD
Raloxifene—CYP2C8—Etoposide—muscle cancer	0.0942	0.132	CbGbCtD
Raloxifene—CYP2B6—Doxorubicin—muscle cancer	0.0848	0.119	CbGbCtD
Raloxifene—CYP3A4—Vincristine—muscle cancer	0.0417	0.0585	CbGbCtD
Raloxifene—CYP3A4—Etoposide—muscle cancer	0.0382	0.0536	CbGbCtD
Raloxifene—CYP3A4—Doxorubicin—muscle cancer	0.0261	0.0365	CbGbCtD
Raloxifene—AOX1—Effects of Nitric Oxide—MB—muscle cancer	0.0191	0.489	CbGpPWpGaD
Raloxifene—Retinal vein thrombosis—Methotrexate—muscle cancer	0.014	0.0672	CcSEcCtD
Raloxifene—Coronary artery disease—Vincristine—muscle cancer	0.00765	0.0368	CcSEcCtD
Raloxifene—Thromboembolic event—Methotrexate—muscle cancer	0.00545	0.0262	CcSEcCtD
Raloxifene—Venous thromboembolism—Doxorubicin—muscle cancer	0.00432	0.0208	CcSEcCtD
Raloxifene—Leukorrhea—Doxorubicin—muscle cancer	0.00271	0.013	CcSEcCtD
Raloxifene—Embolism venous—Doxorubicin—muscle cancer	0.00252	0.0121	CcSEcCtD
Raloxifene—Deep vein thrombosis—Methotrexate—muscle cancer	0.00241	0.0116	CcSEcCtD
Raloxifene—Vaginal discharge—Methotrexate—muscle cancer	0.00241	0.0116	CcSEcCtD
Raloxifene—Embolism—Methotrexate—muscle cancer	0.00229	0.011	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.00221	0.0106	CcSEcCtD
Raloxifene—Vaginal discharge—Doxorubicin—muscle cancer	0.00209	0.01	CcSEcCtD
Raloxifene—Embolism—Doxorubicin—muscle cancer	0.00198	0.00951	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.00198	0.0095	CcSEcCtD
Raloxifene—Pneumonia—Dactinomycin—muscle cancer	0.0019	0.00915	CcSEcCtD
Raloxifene—Neuralgia—Doxorubicin—muscle cancer	0.00183	0.00879	CcSEcCtD
Raloxifene—ESR2—smooth muscle tissue—muscle cancer	0.0018	0.0449	CbGeAlD
Raloxifene—Laryngitis—Doxorubicin—muscle cancer	0.00176	0.00847	CcSEcCtD
Raloxifene—ESR2—renal system—muscle cancer	0.00173	0.0432	CbGeAlD
Raloxifene—Vaginal haemorrhage—Doxorubicin—muscle cancer	0.00172	0.00825	CcSEcCtD
Raloxifene—Pneumonia—Vincristine—muscle cancer	0.0017	0.00818	CcSEcCtD
Raloxifene—Pharyngitis—Dactinomycin—muscle cancer	0.00169	0.00811	CcSEcCtD
Raloxifene—Depression—Vincristine—muscle cancer	0.00169	0.00811	CcSEcCtD
Raloxifene—AOX1—renal system—muscle cancer	0.00167	0.0416	CbGeAlD
Raloxifene—HTR6—head—muscle cancer	0.00165	0.0411	CbGeAlD
Raloxifene—Sweating—Vincristine—muscle cancer	0.00162	0.0078	CcSEcCtD
Raloxifene—Flushing—Dactinomycin—muscle cancer	0.00158	0.00758	CcSEcCtD
Raloxifene—ESR1—embryo—muscle cancer	0.00157	0.0391	CbGeAlD
Raloxifene—Hypoaesthesia—Vincristine—muscle cancer	0.00151	0.00726	CcSEcCtD
Raloxifene—Urinary tract disorder—Vincristine—muscle cancer	0.0015	0.00721	CcSEcCtD
Raloxifene—AOX1—cardiac atrium—muscle cancer	0.00149	0.0372	CbGeAlD
Raloxifene—Connective tissue disorder—Vincristine—muscle cancer	0.00149	0.00717	CcSEcCtD
Raloxifene—Urethral disorder—Vincristine—muscle cancer	0.00149	0.00716	CcSEcCtD
Raloxifene—Neoplasm malignant—Doxorubicin—muscle cancer	0.00149	0.00715	CcSEcCtD
Raloxifene—Vaginal inflammation—Methotrexate—muscle cancer	0.00147	0.00705	CcSEcCtD
Raloxifene—Pulmonary embolism—Methotrexate—muscle cancer	0.00147	0.00705	CcSEcCtD
Raloxifene—Breast pain—Doxorubicin—muscle cancer	0.00146	0.007	CcSEcCtD
Raloxifene—Vasodilation—Doxorubicin—muscle cancer	0.00145	0.00695	CcSEcCtD
Raloxifene—Vasodilation procedure—Doxorubicin—muscle cancer	0.00145	0.00695	CcSEcCtD
Raloxifene—Cystitis noninfective—Methotrexate—muscle cancer	0.00143	0.00689	CcSEcCtD
Raloxifene—Cystitis—Methotrexate—muscle cancer	0.00142	0.00681	CcSEcCtD
Raloxifene—Cardiac disorder—Vincristine—muscle cancer	0.00141	0.00678	CcSEcCtD
Raloxifene—SIGMAR1—smooth muscle tissue—muscle cancer	0.00139	0.0348	CbGeAlD
Raloxifene—HTR2B—smooth muscle tissue—muscle cancer	0.00139	0.0347	CbGeAlD
Raloxifene—Cough increased—Doxorubicin—muscle cancer	0.00139	0.00667	CcSEcCtD
Raloxifene—Vaginal infection—Methotrexate—muscle cancer	0.00139	0.00666	CcSEcCtD
Raloxifene—Pneumonia—Etoposide—muscle cancer	0.00138	0.00663	CcSEcCtD
Raloxifene—Angiopathy—Vincristine—muscle cancer	0.00138	0.00662	CcSEcCtD
Raloxifene—Bladder pain—Methotrexate—muscle cancer	0.00133	0.00638	CcSEcCtD
Raloxifene—AOX1—tendon—muscle cancer	0.0013	0.0324	CbGeAlD
Raloxifene—Vaginal inflammation—Doxorubicin—muscle cancer	0.00127	0.00611	CcSEcCtD
Raloxifene—Pulmonary embolism—Doxorubicin—muscle cancer	0.00127	0.00611	CcSEcCtD
Raloxifene—Myalgia—Dactinomycin—muscle cancer	0.00126	0.00606	CcSEcCtD
Raloxifene—ESR2—vagina—muscle cancer	0.00125	0.0313	CbGeAlD
Raloxifene—Cystitis noninfective—Doxorubicin—muscle cancer	0.00124	0.00597	CcSEcCtD
Raloxifene—ESR1—smooth muscle tissue—muscle cancer	0.00123	0.0307	CbGeAlD
Raloxifene—Cystitis—Doxorubicin—muscle cancer	0.00123	0.0059	CcSEcCtD
Raloxifene—Diabetes mellitus—Methotrexate—muscle cancer	0.00122	0.00589	CcSEcCtD
Raloxifene—Hypoaesthesia—Etoposide—muscle cancer	0.00122	0.00588	CcSEcCtD
Raloxifene—Urinary tract disorder—Etoposide—muscle cancer	0.00122	0.00584	CcSEcCtD
Raloxifene—AOX1—vagina—muscle cancer	0.00121	0.0301	CbGeAlD
Raloxifene—Urethral disorder—Etoposide—muscle cancer	0.00121	0.0058	CcSEcCtD
Raloxifene—SIGMAR1—cardiac atrium—muscle cancer	0.0012	0.03	CbGeAlD
Raloxifene—Infection—Dactinomycin—muscle cancer	0.0012	0.00577	CcSEcCtD
Raloxifene—Vaginal infection—Doxorubicin—muscle cancer	0.0012	0.00577	CcSEcCtD
Raloxifene—Vertigo—Vincristine—muscle cancer	0.00119	0.00571	CcSEcCtD
Raloxifene—ESR1—renal system—muscle cancer	0.00119	0.0296	CbGeAlD
Raloxifene—Thrombocytopenia—Dactinomycin—muscle cancer	0.00118	0.00568	CcSEcCtD
Raloxifene—Cramps of lower extremities—Doxorubicin—muscle cancer	0.00117	0.00561	CcSEcCtD
Raloxifene—ESR2—head—muscle cancer	0.00116	0.0289	CbGeAlD
Raloxifene—Bladder pain—Doxorubicin—muscle cancer	0.00115	0.00552	CcSEcCtD
Raloxifene—Flushing—Etoposide—muscle cancer	0.00114	0.00549	CcSEcCtD
Raloxifene—Cardiac disorder—Etoposide—muscle cancer	0.00114	0.00549	CcSEcCtD
Raloxifene—Myalgia—Vincristine—muscle cancer	0.00113	0.00541	CcSEcCtD
Raloxifene—ESR2—testis—muscle cancer	0.00112	0.0279	CbGeAlD
Raloxifene—Angiopathy—Etoposide—muscle cancer	0.00112	0.00537	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Dactinomycin—muscle cancer	0.0011	0.00529	CcSEcCtD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—TFE3—muscle cancer	0.0011	0.0281	CbGpPWpGaD
Raloxifene—Cerebrovascular accident—Methotrexate—muscle cancer	0.00109	0.00523	CcSEcCtD
Raloxifene—AOX1—testis—muscle cancer	0.00108	0.0269	CbGeAlD
Raloxifene—Infection—Vincristine—muscle cancer	0.00107	0.00515	CcSEcCtD
Raloxifene—Diabetes mellitus—Doxorubicin—muscle cancer	0.00106	0.0051	CcSEcCtD
Raloxifene—Nervous system disorder—Vincristine—muscle cancer	0.00106	0.00509	CcSEcCtD
Raloxifene—Thrombocytopenia—Vincristine—muscle cancer	0.00106	0.00508	CcSEcCtD
Raloxifene—SIGMAR1—tendon—muscle cancer	0.00105	0.0261	CbGeAlD
Raloxifene—HTR2B—tendon—muscle cancer	0.00105	0.0261	CbGeAlD
Raloxifene—Hyperhidrosis—Vincristine—muscle cancer	0.00104	0.00501	CcSEcCtD
Raloxifene—Pain—Dactinomycin—muscle cancer	0.00103	0.00496	CcSEcCtD
Raloxifene—Muscle spasms—Etoposide—muscle cancer	0.00103	0.00495	CcSEcCtD
Raloxifene—SIGMAR1—bone marrow—muscle cancer	0.00101	0.0253	CbGeAlD
Raloxifene—Gastrointestinal pain—Dactinomycin—muscle cancer	0.000988	0.00475	CcSEcCtD
Raloxifene—Hot flush—Doxorubicin—muscle cancer	0.000986	0.00474	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Vincristine—muscle cancer	0.000983	0.00473	CcSEcCtD
Raloxifene—Menopausal symptoms—Doxorubicin—muscle cancer	0.000978	0.0047	CcSEcCtD
Raloxifene—CYP2C8—renal system—muscle cancer	0.000977	0.0244	CbGeAlD
Raloxifene—Insomnia—Vincristine—muscle cancer	0.000976	0.00469	CcSEcCtD
Raloxifene—SIGMAR1—vagina—muscle cancer	0.000972	0.0242	CbGeAlD
Raloxifene—HTR2B—vagina—muscle cancer	0.00097	0.0242	CbGeAlD
Raloxifene—Breast disorder—Methotrexate—muscle cancer	0.000963	0.00463	CcSEcCtD
Raloxifene—Vertigo—Etoposide—muscle cancer	0.000962	0.00463	CcSEcCtD
Raloxifene—Body temperature increased—Dactinomycin—muscle cancer	0.000955	0.00459	CcSEcCtD
Raloxifene—Abdominal pain—Dactinomycin—muscle cancer	0.000955	0.00459	CcSEcCtD
Raloxifene—Loss of consciousness—Etoposide—muscle cancer	0.000941	0.00452	CcSEcCtD
Raloxifene—Cerebrovascular accident—Doxorubicin—muscle cancer	0.000941	0.00452	CcSEcCtD
Raloxifene—Cough—Etoposide—muscle cancer	0.000935	0.00449	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Vincristine—muscle cancer	0.000932	0.00448	CcSEcCtD
Raloxifene—Pain—Vincristine—muscle cancer	0.000923	0.00444	CcSEcCtD
Raloxifene—CYP19A1—head—muscle cancer	0.000913	0.0228	CbGeAlD
Raloxifene—Chest pain—Etoposide—muscle cancer	0.000912	0.00438	CcSEcCtD
Raloxifene—Migraine—Doxorubicin—muscle cancer	0.000908	0.00436	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000906	0.00435	CcSEcCtD
Raloxifene—HTR2B—head—muscle cancer	0.000896	0.0223	CbGeAlD
Raloxifene—Gastrointestinal pain—Vincristine—muscle cancer	0.000882	0.00424	CcSEcCtD
Raloxifene—CYP19A1—testis—muscle cancer	0.000882	0.022	CbGeAlD
Raloxifene—CYP2B6—renal system—muscle cancer	0.000877	0.0219	CbGeAlD
Raloxifene—ESR2—SIDS Susceptibility Pathways—TP73—muscle cancer	0.000869	0.0223	CbGpPWpGaD
Raloxifene—Infection—Etoposide—muscle cancer	0.000868	0.00417	CcSEcCtD
Raloxifene—SIGMAR1—testis—muscle cancer	0.000868	0.0216	CbGeAlD
Raloxifene—ESR1—vagina—muscle cancer	0.000859	0.0214	CbGeAlD
Raloxifene—Thrombocytopenia—Etoposide—muscle cancer	0.000856	0.00411	CcSEcCtD
Raloxifene—Abdominal pain—Vincristine—muscle cancer	0.000853	0.0041	CcSEcCtD
Raloxifene—Body temperature increased—Vincristine—muscle cancer	0.000853	0.0041	CcSEcCtD
Raloxifene—Skin disorder—Etoposide—muscle cancer	0.000849	0.00408	CcSEcCtD
Raloxifene—Hyperhidrosis—Etoposide—muscle cancer	0.000845	0.00406	CcSEcCtD
Raloxifene—Breast disorder—Doxorubicin—muscle cancer	0.000834	0.00401	CcSEcCtD
Raloxifene—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000831	0.00399	CcSEcCtD
Raloxifene—Diarrhoea—Dactinomycin—muscle cancer	0.000826	0.00397	CcSEcCtD
Raloxifene—Pneumonia—Methotrexate—muscle cancer	0.000826	0.00397	CcSEcCtD
Raloxifene—Depression—Methotrexate—muscle cancer	0.000819	0.00393	CcSEcCtD
Raloxifene—CYP19A1—FSH signaling pathway—FOXO1—muscle cancer	0.000815	0.0209	CbGpPWpGaD
Raloxifene—Conjunctivitis—Methotrexate—muscle cancer	0.000798	0.00384	CcSEcCtD
Raloxifene—Influenza—Doxorubicin—muscle cancer	0.000797	0.00383	CcSEcCtD
Raloxifene—ESR1—head—muscle cancer	0.000794	0.0198	CbGeAlD
Raloxifene—Sweating—Methotrexate—muscle cancer	0.000787	0.00378	CcSEcCtD
Raloxifene—Vomiting—Dactinomycin—muscle cancer	0.000768	0.00369	CcSEcCtD
Raloxifene—ESR1—testis—muscle cancer	0.000767	0.0191	CbGeAlD
Raloxifene—Bronchitis—Doxorubicin—muscle cancer	0.000767	0.00369	CcSEcCtD
Raloxifene—Rash—Dactinomycin—muscle cancer	0.000762	0.00366	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Etoposide—muscle cancer	0.000755	0.00363	CcSEcCtD
Raloxifene—Pain—Etoposide—muscle cancer	0.000748	0.00359	CcSEcCtD
Raloxifene—Diarrhoea—Vincristine—muscle cancer	0.000738	0.00355	CcSEcCtD
Raloxifene—Pharyngitis—Methotrexate—muscle cancer	0.000731	0.00352	CcSEcCtD
Raloxifene—Urinary tract disorder—Methotrexate—muscle cancer	0.000728	0.0035	CcSEcCtD
Raloxifene—Weight increased—Doxorubicin—muscle cancer	0.000726	0.00349	CcSEcCtD
Raloxifene—Urethral disorder—Methotrexate—muscle cancer	0.000722	0.00347	CcSEcCtD
Raloxifene—Nausea—Dactinomycin—muscle cancer	0.000717	0.00345	CcSEcCtD
Raloxifene—Pneumonia—Doxorubicin—muscle cancer	0.000715	0.00344	CcSEcCtD
Raloxifene—Gastrointestinal pain—Etoposide—muscle cancer	0.000715	0.00344	CcSEcCtD
Raloxifene—Dizziness—Vincristine—muscle cancer	0.000714	0.00343	CcSEcCtD
Raloxifene—CYP2C8—vagina—muscle cancer	0.000708	0.0176	CbGeAlD
Raloxifene—Body temperature increased—Etoposide—muscle cancer	0.000691	0.00332	CcSEcCtD
Raloxifene—Abdominal pain—Etoposide—muscle cancer	0.000691	0.00332	CcSEcCtD
Raloxifene—Urinary tract infection—Doxorubicin—muscle cancer	0.000691	0.00332	CcSEcCtD
Raloxifene—Conjunctivitis—Doxorubicin—muscle cancer	0.000691	0.00332	CcSEcCtD
Raloxifene—Vomiting—Vincristine—muscle cancer	0.000686	0.0033	CcSEcCtD
Raloxifene—Cardiac disorder—Methotrexate—muscle cancer	0.000684	0.00329	CcSEcCtD
Raloxifene—Sweating—Doxorubicin—muscle cancer	0.000682	0.00328	CcSEcCtD
Raloxifene—Rash—Vincristine—muscle cancer	0.00068	0.00327	CcSEcCtD
Raloxifene—Dermatitis—Vincristine—muscle cancer	0.00068	0.00327	CcSEcCtD
Raloxifene—Headache—Vincristine—muscle cancer	0.000676	0.00325	CcSEcCtD
Raloxifene—Angiopathy—Methotrexate—muscle cancer	0.000669	0.00321	CcSEcCtD
Raloxifene—Sinusitis—Doxorubicin—muscle cancer	0.000667	0.00321	CcSEcCtD
Raloxifene—CYP3A4—renal system—muscle cancer	0.000662	0.0165	CbGeAlD
Raloxifene—ESR1—Regulation of Telomerase—WT1—muscle cancer	0.000646	0.0165	CbGpPWpGaD
Raloxifene—Nausea—Vincristine—muscle cancer	0.000641	0.00308	CcSEcCtD
Raloxifene—Rhinitis—Doxorubicin—muscle cancer	0.00064	0.00307	CcSEcCtD
Raloxifene—CYP2B6—vagina—muscle cancer	0.000635	0.0158	CbGeAlD
Raloxifene—Hypoaesthesia—Doxorubicin—muscle cancer	0.000635	0.00305	CcSEcCtD
Raloxifene—Pharyngitis—Doxorubicin—muscle cancer	0.000633	0.00304	CcSEcCtD
Raloxifene—CYP2C8—testis—muscle cancer	0.000632	0.0157	CbGeAlD
Raloxifene—Urinary tract disorder—Doxorubicin—muscle cancer	0.00063	0.00303	CcSEcCtD
Raloxifene—Oedema peripheral—Doxorubicin—muscle cancer	0.000629	0.00302	CcSEcCtD
Raloxifene—Connective tissue disorder—Doxorubicin—muscle cancer	0.000627	0.00301	CcSEcCtD
Raloxifene—Urethral disorder—Doxorubicin—muscle cancer	0.000626	0.00301	CcSEcCtD
Raloxifene—AOX1—Tryptophan metabolism—MDM2—muscle cancer	0.000618	0.0158	CbGpPWpGaD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—MYOD1—muscle cancer	0.000604	0.0155	CbGpPWpGaD
Raloxifene—Diarrhoea—Etoposide—muscle cancer	0.000598	0.00287	CcSEcCtD
Raloxifene—Cardiac disorder—Doxorubicin—muscle cancer	0.000592	0.00285	CcSEcCtD
Raloxifene—Flushing—Doxorubicin—muscle cancer	0.000592	0.00285	CcSEcCtD
Raloxifene—CYP2B6—head—muscle cancer	0.000587	0.0146	CbGeAlD
Raloxifene—Angiopathy—Doxorubicin—muscle cancer	0.000579	0.00278	CcSEcCtD
Raloxifene—Dizziness—Etoposide—muscle cancer	0.000578	0.00278	CcSEcCtD
Raloxifene—Vertigo—Methotrexate—muscle cancer	0.000576	0.00277	CcSEcCtD
Raloxifene—CYP2B6—testis—muscle cancer	0.000567	0.0141	CbGeAlD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.00056	0.0144	CbGpPWpGaD
Raloxifene—Cough—Methotrexate—muscle cancer	0.00056	0.00269	CcSEcCtD
Raloxifene—Vomiting—Etoposide—muscle cancer	0.000556	0.00267	CcSEcCtD
Raloxifene—Rash—Etoposide—muscle cancer	0.000551	0.00265	CcSEcCtD
Raloxifene—Dermatitis—Etoposide—muscle cancer	0.000551	0.00265	CcSEcCtD
Raloxifene—Headache—Etoposide—muscle cancer	0.000548	0.00263	CcSEcCtD
Raloxifene—Flatulence—Doxorubicin—muscle cancer	0.000547	0.00263	CcSEcCtD
Raloxifene—Myalgia—Methotrexate—muscle cancer	0.000546	0.00263	CcSEcCtD
Raloxifene—Chest pain—Methotrexate—muscle cancer	0.000546	0.00263	CcSEcCtD
Raloxifene—Arthralgia—Methotrexate—muscle cancer	0.000546	0.00263	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000542	0.00261	CcSEcCtD
Raloxifene—Muscle spasms—Doxorubicin—muscle cancer	0.000534	0.00257	CcSEcCtD
Raloxifene—Infection—Methotrexate—muscle cancer	0.00052	0.0025	CcSEcCtD
Raloxifene—Nausea—Etoposide—muscle cancer	0.000519	0.0025	CcSEcCtD
Raloxifene—Nervous system disorder—Methotrexate—muscle cancer	0.000513	0.00247	CcSEcCtD
Raloxifene—Thrombocytopenia—Methotrexate—muscle cancer	0.000513	0.00246	CcSEcCtD
Raloxifene—Skin disorder—Methotrexate—muscle cancer	0.000509	0.00244	CcSEcCtD
Raloxifene—Hyperhidrosis—Methotrexate—muscle cancer	0.000506	0.00243	CcSEcCtD
Raloxifene—Vertigo—Doxorubicin—muscle cancer	0.000499	0.0024	CcSEcCtD
Raloxifene—Syncope—Doxorubicin—muscle cancer	0.000498	0.00239	CcSEcCtD
Raloxifene—Loss of consciousness—Doxorubicin—muscle cancer	0.000488	0.00235	CcSEcCtD
Raloxifene—Cough—Doxorubicin—muscle cancer	0.000485	0.00233	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Methotrexate—muscle cancer	0.000477	0.00229	CcSEcCtD
Raloxifene—Insomnia—Methotrexate—muscle cancer	0.000474	0.00228	CcSEcCtD
Raloxifene—Chest pain—Doxorubicin—muscle cancer	0.000473	0.00227	CcSEcCtD
Raloxifene—Myalgia—Doxorubicin—muscle cancer	0.000473	0.00227	CcSEcCtD
Raloxifene—Arthralgia—Doxorubicin—muscle cancer	0.000473	0.00227	CcSEcCtD
Raloxifene—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.00047	0.00226	CcSEcCtD
Raloxifene—Dyspepsia—Methotrexate—muscle cancer	0.000461	0.00222	CcSEcCtD
Raloxifene—CYP2B6—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000457	0.0117	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.000452	0.0116	CbGpPWpGaD
Raloxifene—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000452	0.00217	CcSEcCtD
Raloxifene—Infection—Doxorubicin—muscle cancer	0.00045	0.00216	CcSEcCtD
Raloxifene—Pain—Methotrexate—muscle cancer	0.000448	0.00215	CcSEcCtD
Raloxifene—Shock—Doxorubicin—muscle cancer	0.000446	0.00214	CcSEcCtD
Raloxifene—Nervous system disorder—Doxorubicin—muscle cancer	0.000445	0.00214	CcSEcCtD
Raloxifene—Thrombocytopenia—Doxorubicin—muscle cancer	0.000444	0.00213	CcSEcCtD
Raloxifene—Skin disorder—Doxorubicin—muscle cancer	0.00044	0.00212	CcSEcCtD
Raloxifene—Hyperhidrosis—Doxorubicin—muscle cancer	0.000438	0.00211	CcSEcCtD
Raloxifene—Gastrointestinal pain—Methotrexate—muscle cancer	0.000428	0.00206	CcSEcCtD
Raloxifene—Body temperature increased—Methotrexate—muscle cancer	0.000414	0.00199	CcSEcCtD
Raloxifene—Abdominal pain—Methotrexate—muscle cancer	0.000414	0.00199	CcSEcCtD
Raloxifene—Musculoskeletal discomfort—Doxorubicin—muscle cancer	0.000413	0.00199	CcSEcCtD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—FOXO4—muscle cancer	0.00041	0.0105	CbGpPWpGaD
Raloxifene—Insomnia—Doxorubicin—muscle cancer	0.00041	0.00197	CcSEcCtD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.00041	0.0105	CbGpPWpGaD
Raloxifene—Dyspepsia—Doxorubicin—muscle cancer	0.000399	0.00192	CcSEcCtD
Raloxifene—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000391	0.00188	CcSEcCtD
Raloxifene—Pain—Doxorubicin—muscle cancer	0.000388	0.00186	CcSEcCtD
Raloxifene—Gastrointestinal pain—Doxorubicin—muscle cancer	0.000371	0.00178	CcSEcCtD
Raloxifene—Abdominal pain—Doxorubicin—muscle cancer	0.000358	0.00172	CcSEcCtD
Raloxifene—Body temperature increased—Doxorubicin—muscle cancer	0.000358	0.00172	CcSEcCtD
Raloxifene—Diarrhoea—Methotrexate—muscle cancer	0.000358	0.00172	CcSEcCtD
Raloxifene—AOX1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—muscle cancer	0.000358	0.00917	CbGpPWpGaD
Raloxifene—EBP—Metabolism—FH—muscle cancer	0.000357	0.00914	CbGpPWpGaD
Raloxifene—Dizziness—Methotrexate—muscle cancer	0.000346	0.00166	CcSEcCtD
Raloxifene—ESR1—Signaling mediated by p38-alpha and p38-beta—PTGS2—muscle cancer	0.000343	0.00879	CbGpPWpGaD
Raloxifene—Vomiting—Methotrexate—muscle cancer	0.000333	0.0016	CcSEcCtD
Raloxifene—Rash—Methotrexate—muscle cancer	0.00033	0.00159	CcSEcCtD
Raloxifene—Dermatitis—Methotrexate—muscle cancer	0.00033	0.00159	CcSEcCtD
Raloxifene—Headache—Methotrexate—muscle cancer	0.000328	0.00158	CcSEcCtD
Raloxifene—ESR1—Leptin signaling pathway—FOXO1—muscle cancer	0.000322	0.00826	CbGpPWpGaD
Raloxifene—CYP19A1—Tryptophan metabolism—MDM2—muscle cancer	0.000319	0.00819	CbGpPWpGaD
Raloxifene—ESR1—FOXM1 transcription factor network—CDKN2A—muscle cancer	0.000317	0.00813	CbGpPWpGaD
Raloxifene—Nausea—Methotrexate—muscle cancer	0.000311	0.00149	CcSEcCtD
Raloxifene—Diarrhoea—Doxorubicin—muscle cancer	0.00031	0.00149	CcSEcCtD
Raloxifene—ESR1—Regulation of nuclear SMAD2/3 signaling—FOXO1—muscle cancer	0.000303	0.00777	CbGpPWpGaD
Raloxifene—Dizziness—Doxorubicin—muscle cancer	0.0003	0.00144	CcSEcCtD
Raloxifene—Vomiting—Doxorubicin—muscle cancer	0.000288	0.00139	CcSEcCtD
Raloxifene—Rash—Doxorubicin—muscle cancer	0.000286	0.00137	CcSEcCtD
Raloxifene—Dermatitis—Doxorubicin—muscle cancer	0.000286	0.00137	CcSEcCtD
Raloxifene—Headache—Doxorubicin—muscle cancer	0.000284	0.00137	CcSEcCtD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000283	0.00724	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—PTGS2—muscle cancer	0.000276	0.00707	CbGpPWpGaD
Raloxifene—ESR2—Generic Transcription Pathway—MED12—muscle cancer	0.000274	0.00702	CbGpPWpGaD
Raloxifene—Nausea—Doxorubicin—muscle cancer	0.000269	0.00129	CcSEcCtD
Raloxifene—ESR1—Signaling by ERBB4—FOXO4—muscle cancer	0.000248	0.00636	CbGpPWpGaD
Raloxifene—ESR1—Aryl Hydrocarbon Receptor—VEGFA—muscle cancer	0.000217	0.00557	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—CDKN2A—muscle cancer	0.000211	0.0054	CbGpPWpGaD
Raloxifene—HTR6—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.00021	0.00538	CbGpPWpGaD
Raloxifene—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000208	0.00532	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000207	0.0053	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000206	0.00527	CbGpPWpGaD
Raloxifene—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—muscle cancer	0.000204	0.00523	CbGpPWpGaD
Raloxifene—EBP—Metabolism—MED12—muscle cancer	0.000202	0.00517	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—FH—muscle cancer	0.000198	0.00507	CbGpPWpGaD
Raloxifene—HTR2B—GPCRs, Class A Rhodopsin-like—CNR1—muscle cancer	0.000191	0.00491	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000184	0.00472	CbGpPWpGaD
Raloxifene—EBP—Metabolism—ENO2—muscle cancer	0.000184	0.00471	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—FOXO1—muscle cancer	0.000183	0.0047	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000182	0.00466	CbGpPWpGaD
Raloxifene—HTR6—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.00018	0.00461	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000175	0.00449	CbGpPWpGaD
Raloxifene—ESR1—LKB1 signaling events—TP53—muscle cancer	0.000173	0.00444	CbGpPWpGaD
Raloxifene—HTR2B—Class A/1 (Rhodopsin-like receptors)—CNR1—muscle cancer	0.000164	0.0042	CbGpPWpGaD
Raloxifene—ESR2—SIDS Susceptibility Pathways—VEGFA—muscle cancer	0.000162	0.00416	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—PTCH1—muscle cancer	0.000162	0.00415	CbGpPWpGaD
Raloxifene—CYP2C8—Arachidonic acid metabolism—PTGS2—muscle cancer	0.000157	0.00402	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—PTCH1—muscle cancer	0.000148	0.00379	CbGpPWpGaD
Raloxifene—EBP—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	0.000144	0.00368	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—KIT—muscle cancer	0.00014	0.00358	CbGpPWpGaD
Raloxifene—ESR1—Generic Transcription Pathway—MED12—muscle cancer	0.000138	0.00354	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.000138	0.00353	CbGpPWpGaD
Raloxifene—HTR6—GPCR ligand binding—CNR1—muscle cancer	0.000137	0.00351	CbGpPWpGaD
Raloxifene—ESR2—Gene Expression—MED12—muscle cancer	0.000132	0.00338	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—MED12—muscle cancer	0.00013	0.00332	CbGpPWpGaD
Raloxifene—HTR2B—GPCR ligand binding—CNR1—muscle cancer	0.000125	0.0032	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KIDINS220—muscle cancer	0.000125	0.0032	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.000123	0.00316	CbGpPWpGaD
Raloxifene—AOX1—Disease—ENO2—muscle cancer	0.000122	0.00312	CbGpPWpGaD
Raloxifene—ESR1—AP-1 transcription factor network—TP53—muscle cancer	0.000117	0.00301	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KIDINS220—muscle cancer	0.000114	0.00292	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—MED12—muscle cancer	0.000112	0.00286	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.000111	0.00283	CbGpPWpGaD
Raloxifene—AOX1—Disease—HMGA1—muscle cancer	0.00011	0.00283	CbGpPWpGaD
Raloxifene—ESR1—Signaling by ERBB4—MDM2—muscle cancer	0.00011	0.00282	CbGpPWpGaD
Raloxifene—ESR2—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000104	0.00267	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—FH—muscle cancer	0.000102	0.00262	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—ENO2—muscle cancer	0.000102	0.00261	CbGpPWpGaD
Raloxifene—AOX1—Disease—FOXO4—muscle cancer	9.91e-05	0.00254	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KIDINS220—muscle cancer	9.49e-05	0.00243	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	9.37e-05	0.0024	CbGpPWpGaD
Raloxifene—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	9.32e-05	0.00239	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	9.16e-05	0.00235	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	8.83e-05	0.00226	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	8.39e-05	0.00215	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—PTCH1—muscle cancer	8.32e-05	0.00213	CbGpPWpGaD
Raloxifene—HTR6—GPCR downstream signaling—CNR1—muscle cancer	7.73e-05	0.00198	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—PTCH1—muscle cancer	7.59e-05	0.00195	CbGpPWpGaD
Raloxifene—AOX1—Disease—FOXO1—muscle cancer	7.32e-05	0.00188	CbGpPWpGaD
Raloxifene—CYP19A1—Integrated Breast Cancer Pathway—TP53—muscle cancer	7.08e-05	0.00182	CbGpPWpGaD
Raloxifene—HTR2B—GPCR downstream signaling—CNR1—muscle cancer	7.06e-05	0.00181	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—MED12—muscle cancer	7.05e-05	0.00181	CbGpPWpGaD
Raloxifene—HTR6—Signaling by GPCR—CNR1—muscle cancer	7.02e-05	0.0018	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	6.95e-05	0.00178	CbGpPWpGaD
Raloxifene—ESR1—Gene Expression—MED12—muscle cancer	6.65e-05	0.0017	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—FH—muscle cancer	6.56e-05	0.00168	CbGpPWpGaD
Raloxifene—HTR2B—Signaling by GPCR—CNR1—muscle cancer	6.41e-05	0.00164	CbGpPWpGaD
Raloxifene—EBP—Metabolism—PTGS2—muscle cancer	6.4e-05	0.00164	CbGpPWpGaD
Raloxifene—ESR1—Integrated Breast Cancer Pathway—TP53—muscle cancer	6.34e-05	0.00163	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—MED12—muscle cancer	5.77e-05	0.00148	CbGpPWpGaD
Raloxifene—AOX1—Disease—KIT—muscle cancer	5.58e-05	0.00143	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—FH—muscle cancer	5.56e-05	0.00142	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—ENO2—muscle cancer	5.26e-05	0.00135	CbGpPWpGaD
Raloxifene—ESR1—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	5.25e-05	0.00135	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—PTCH1—muscle cancer	4.91e-05	0.00126	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—PTCH1—muscle cancer	4.48e-05	0.00115	CbGpPWpGaD
Raloxifene—AOX1—Disease—MDM2—muscle cancer	4.39e-05	0.00113	CbGpPWpGaD
Raloxifene—AOX1—Disease—PTGS2—muscle cancer	4.23e-05	0.00109	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FOXO4—muscle cancer	4.23e-05	0.00108	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—CNR1—muscle cancer	4.15e-05	0.00106	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	4.12e-05	0.00106	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FOXO4—muscle cancer	3.86e-05	0.000989	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—CNR1—muscle cancer	3.79e-05	0.00097	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—PTCH1—muscle cancer	3.74e-05	0.000958	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—MED12—muscle cancer	3.71e-05	0.000951	CbGpPWpGaD
Raloxifene—AOX1—Metabolism—PTGS2—muscle cancer	3.55e-05	0.000909	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—IGF2—muscle cancer	3.39e-05	0.000869	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—ENO2—muscle cancer	3.38e-05	0.000867	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FOXO4—muscle cancer	3.21e-05	0.000824	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—CNR1—muscle cancer	3.15e-05	0.000808	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—MED12—muscle cancer	3.14e-05	0.000805	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—FOXO1—muscle cancer	3.12e-05	0.0008	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—IGF2—muscle cancer	3.1e-05	0.000793	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—FH—muscle cancer	2.98e-05	0.000765	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—ENO2—muscle cancer	2.86e-05	0.000734	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—FOXO1—muscle cancer	2.85e-05	0.00073	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—IGF2—muscle cancer	2.58e-05	0.000661	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—KIT—muscle cancer	2.38e-05	0.00061	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—FOXO1—muscle cancer	2.37e-05	0.000608	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—muscle cancer	2.24e-05	0.000574	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—KIT—muscle cancer	2.17e-05	0.000556	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—MDM2—muscle cancer	1.87e-05	0.00048	CbGpPWpGaD
Raloxifene—CYP19A1—Metabolism—PTGS2—muscle cancer	1.83e-05	0.00047	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—KIT—muscle cancer	1.81e-05	0.000463	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—MDM2—muscle cancer	1.71e-05	0.000438	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—MED12—muscle cancer	1.69e-05	0.000432	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—ENO2—muscle cancer	1.54e-05	0.000394	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—MDM2—muscle cancer	1.42e-05	0.000365	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—VEGFA—muscle cancer	1.42e-05	0.000365	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—VEGFA—muscle cancer	1.3e-05	0.000333	CbGpPWpGaD
Raloxifene—CYP2B6—Metabolism—PTGS2—muscle cancer	1.18e-05	0.000302	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—VEGFA—muscle cancer	1.08e-05	0.000277	CbGpPWpGaD
Raloxifene—HTR6—Signaling Pathways—TP53—muscle cancer	1.07e-05	0.000275	CbGpPWpGaD
Raloxifene—CYP2C8—Metabolism—PTGS2—muscle cancer	9.97e-06	0.000256	CbGpPWpGaD
Raloxifene—HTR2B—Signaling Pathways—TP53—muscle cancer	9.81e-06	0.000251	CbGpPWpGaD
Raloxifene—ESR1—Signaling Pathways—TP53—muscle cancer	8.17e-06	0.000209	CbGpPWpGaD
Raloxifene—CYP3A4—Metabolism—PTGS2—muscle cancer	5.35e-06	0.000137	CbGpPWpGaD
